Incidence of hand–foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen
- First Online:
- 287 Downloads
Hand–foot syndrome (HFS) is a limiting toxicity of capecitabine, which is not life-threatening but could compromise capecitabine efficacy.
Materials and methods
This phase II, multicenter, non-controlled study assessed the safety, particularly grade three HFS incidence, and efficacy of four capecitabine-based chemotherapy regimens [cisplatin/capecitabine (CX), epirubicin/cisplatin/capecitabine (ECX), epirubicin/oxaliplatin/capecitabine (EOX) and docetaxel/cisplatin/capecitabine (DCX)] as first-line treatment for advanced and/or metastatic gastric cancer.
One hundred and eight patients were assigned to one of the four treatment groups, according to investigator’s criteria, and grouped together for both safety and efficacy primary analyses. HFS was reported in 31 patients (19.6 %) and its first presentation occurred at a median of 72 days (range 19–209 days). Grade 3 HFS developed in 6.3, 5.2, 3.7 and 2.4 %, of patients receiving ECX, DCX, EOX or CX chemotherapy regimen, respectively. Capecitabine dose reduction/discontinuation due to HFS was required in 5.7 % of patients (9/158). The most common (>10 %) grade 3–4 treatment-related AEs were neutropenia (15.2 %), asthenia (12.0 %) and diarrhoea (11.4 %).
A moderate incidence of HFS was reported in patients treated with capecitabine, which generally presented late and required dose reduction in <1/3 of patients. The results suggest that capecitabine may be useful in combination with standard fluorouracil-based regimens in patients with advanced and/or metastatic gastric cancer with favourable safety profile.
KeywordsCapecitabine stomach neoplasms Neoplasm metastasis Fluorouracil Foot dermatoses/chemically induced Hand dermatoses/chemically induced
- 2.Cabanes A, Perez-Gomez B, Aragones N, Pollan M, Lopez-Abente G (2009) La situación del cáncer en España, 1975–2006. INE-MadridGoogle Scholar
- 3.Altekruse SF, Kosary CL, Krapcho M et al (2011) SEER cancer statistics review, 1975–2007, National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010
- 18.National Institute for Health and Clinical Excellence (2010) Capecitabine for the treatment of advanced gastric cancer. NICE technology appraisal guidance 191 www.nice.org.uk/guidance/TA191. Accessed 19 Jan 2011
- 20.Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst 92(3):205–216PubMedCrossRefGoogle Scholar
- 24.Capecitabine -SPC (2010) Xeloda (capecitabine)–Roche Pharma AG. Summary of Product CharacteristicsGoogle Scholar
- 25.Oxaliplatin-SPC (2010) Oxaliplatin. Summary of Product CharacteristicsGoogle Scholar
- 26.Epirubicin-SPC (2010) Epirubicin. Summary of Product CharacteristicsGoogle Scholar
- 27.Martinez Amores B, Alsina M, Jiménez E et al (2011) Observational transversal study to relate functional status and age with the doublet or triplet chemotherapy based on capecitabine in advanced gastric cancer patients. J Clin Oncol 29: (suppl 4), abstract 59Google Scholar